Affordable Access

deepdyve-link
Publisher Website

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017

Authors
  • Shimbashi, Reiko
  • Suzuki, Motoi
  • Chang, Bin
  • Watanabe, Hiroshi
  • Tanabe, Yoshinari
  • Kuronuma, Koji
  • Oshima, Kengo
  • Maruyama, Takaya
  • Takeda, Hiroaki
  • Kasahara, Kei
  • Fujita, Jiro
  • Nishi, Junichiro
  • Kubota, Tetsuya
  • Tanaka-Taya, Keiko
  • Matsui, Tamano
  • Sunagawa, Tomimasa
  • Oishi, Kazunori
Type
Published Article
Journal
Emerging Infectious Diseases
Publisher
Centers For Disease Control and Prevention
Publication Date
Oct 01, 2020
Volume
26
Issue
10
Pages
2378–2386
Identifiers
DOI: 10.3201/eid2610.191531
PMID: 32946721
PMCID: PMC7510723
Source
PubMed Central
Keywords
License
Unknown

Abstract

The decline in the proportion of pneumococcal conjugate vaccine (PCV)–covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients > 20 years of age through enhanced IPD surveillance during April 2013–December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.

Report this publication

Statistics

Seen <100 times